Role of clozapine in treatment-resistant schizophrenia

Advances in Biological Psychiatry

Volumn 26, Issue , 2010, Pages 114-128

  Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865344205     PISSN: 03787354     EISSN: 16622774     Source Type: Book Series    
DOI: 10.1159/000319812     Document Type: Article

References (79)

1. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK: The de facto US mental and addictive disorders service system: Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiat 1993;50:85-94.
2. Meltzer HY: Treatment-resistant schizophrenia - the role of clozapine. Curr Med Res Opin 1997;14:1-20.
3. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J: The economic burden of schizophrenia in the United States in 2002. J Clin Psychiat 2005;66:1122-1129.
4. Blomqvist AG, Leger PT, Hoch JS: The cost of schizophrenia: Lessons from an international comparison. J Ment Health Policy Econ 2006;9:177-183.
5. Meltzer D, Basu A, Meltzer HY: Comparative effectiveness research for antipsychotic medications: How much is enough? Health Affairs 2009;28: W794-W808.
6. Kunikata H, Mino Y, Nakajima K: Quality of life of schizophrenic patients living in the community: The relationships with personal characteristics, objective indicators and self-esteem. Psychiat Clin Neurosci 2005;59:163-169.
7. Awad AG, Voruganti LN: The burden of schizophrenia on caregivers: A review. Pharmacoeconomics 2008;26:149-162.
8. Meltzer HY: Suicidality in schizophrenia: A review of the evidence for risk factors and treatment options. Curr Psychiat Rep 2002;4:279-283.
9. Goldberg SC, Mattsson N, Cole JO, Klerman GL: Prediction of improvement in schizophrenia under four phenothiazines. Arch Gen Psychiat 1967;16: 107-117.
10. Carlsson A, Lindqvist M: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963;20:140-144.
11. Creese I, Burt DR, Snyder SH: Dopamine receptors and average clinical doses. Science 1976;194:546.
12. Stille G, Lauener H, Eichenberger E: The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)- 5H-dibenzo(b,e)(1,4)diazepine (clozapine).Farmaco Prat 1971;26:603-625.
13. Hippius H: The history of clozapine. Psychopharmacol (Berl) 1989;99:S3-S5.
14. Angst J, Bemte D, Berner P, Heimann H, Helmchen H, Hippius, H: Das Klinische Wirkungsbild von Clozapine. Pharmacopsychiat 1971;4:201-221.
15. Matz R, Rick W, Thompson H, Gershon S: Clozapine - a potential antipsychotic agent without extrapyramidal manifestations. Curr Ther Res Clin Exp 1974; 16:687-695.
16. Simpson GM, Varga E: Clozapine-a new antipsychotic agent. Curr Ther Res Clin Exp 1974;16:679- 686.
17. Faltus F, Hynek K, Dolezalova V, Kumnickova Z, Zemek P: Experience in the treatment of schizophrenia with clozapine. Act Nerv Super (Praha) ;15:95.
18. Chouinard G, Annable L: Clozapine in the treatment of newly admitted schizophrenic patients: A pilot study. J Clin Pharmacol 1976;16:289-297.
19. Panteleeva GP, Kovskaya MY, Belyaev BS, Minsker EI, Vynar O, Ceskova E, Svetska J, Libiger J, Korinkova V, Novotny V, et al: Clozapine in the treatment of schizophrenic patients: An international multicenter trial. Clin Ther 1987;10:57-68.
20. Small JG, Milstein V, Marhenke JD, Hall DD, Kellams JJ: Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment- resistant psychosis. J Clin Psychiat 1987;48: 263-267.
21. Rodova A, Svestka J, Nahunek K, Ceskova E: A blind comparison of clozapine and perphenazine in schizophrenics. Act Nerv Super (Praha) 1973;15:94-95.
22. Ekblom B, Haggstrom JE: Clozapine (Leponex) compared with chlorpromazine: A double-blind evaluation of pharmacological and clinical properties. Curr Ther Res Clin Exp 1974;16:945-957.
23. Gerlach J, Koppelhus P, Helweg E, Monrad A: Clozapine and haloperidol in a single-blind crossover trial: Therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 1974;50:410-424.
24. van Praag HM, Korf J, Dols LC: Clozapine versus perphenazine: The value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity. Br J Psychiat 1976;129:547-555.
25. Chiu E, Burrows G, Stevenson J: Double-blind comparison of clozapine with chlorpromazine in acute schizophrenic illness. Aust N Z J Psychiat 1976;10: 343-347.
26. Fischer-Cornelssen KA, Ferner UJ: An example of European multicenter trials: Multispectral analysis of clozapine. Psychopharmacol Bull 1976;12:34-39.
27. Shopsin B, Klein H, Aaronsom M, Collora M: Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: A controlled, double-blind comparison. Arch Gen Psychiat 1979;36:657-664.
28. Gelenberg AJ, Doller JC: Clozapine versus chlorpromazine for the treatment of schizophrenia: Preliminary results from a double-blind study. J Clin Psychiat 1979;40:238-240.
29. Simpson GM, Lee JH, Shrivastava RK: Clozapine in tardive dyskinesia. Psychopharmacol (Berl) 1978;56: 75-80.
30. Meltzer HY, Luchins DJ: Effect of clozapine in severe tardive dyskinesia: A case report. J Clin Psychopharmacol 1984;4:286-287.
31. Idanpaan-Heikkila J, Alhava E, Olkinuora M, Palva I: Letter: Clozapine and agranulocytosis. Lancet 1975;2:611.
32. Idanpaan-Heikkila J, Alhava E, Olkinuora M, Palva IP: Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. Eur J Clin Pharmacol 1977;11:193-198.
33. Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P: Agranulocytosis in patients treated with clozapine: A study of the Finnish epidemic. Acta Psychiatr Scand 1977;56:241-248.
34. Gerson SL, Meltzer H: Mechanisms of clozapineinduced agranulocytosis. Drug Saf 1992;7:17-25.
35. Meltzer HY, Lee MA, Ranjan R, Mason EA, Cola PA: Relapse following clozapine withdrawal: Effect of neuroleptic drugs and cyproheptadine. Psychopharmacol (Berl) 1996;124:176-187.
36. Brenner H, Merlo M: Definition of therapy-resistant schizophrenia and its assessment. Eur Psychiat 1995;10:11S-17S
37. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: A doubleblind comparison with chlorpromazine. Arch Gen Psychiat 1988;45:789-796.
38. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller del D, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiat 2007;68:1751-1762.
39. Meltzer HY: Duration of a clozapine trial in neuroleptic- resistant schizophrenia. Arch Gen Psychiat 1989;46:672.
40. Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J: A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report Psychopharmacol (Berl) 1989;99: S68-S72.
41. Meltzer HY, Bastani B, Ramirez L, Matsubara S: Clozapine: New research on efficacy and mechanism of action. Eur Arch Psychiat Neurol Sci 1989;238: 332-339.
42. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744-1752.
43. Kane JM, Meltzer HY, Carson WH Jr, McQuade RD, Marcus RN, Sanchez R, Aripiprazole Study Group: Aripiprazole for treatment-resistant schizophrenia: Results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiat 2007;68:213-223.
44. Lindstrom LH: The effect of long-term treatment with clozapine in schizophrenia: A retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988;77:524-529.
45. Leppig M, Bosch B, Naber D, Hippius H: Clozapine in the treatment of 121 out-patients. Psychopharmacology (Berl) 1989;99:S77-S79.
46. Naber D, Leppig M, Grohmann R, Hippius H: Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients. Psychopharmacol (Berl) 1989;99:S73-S76.
47. Claghorn J, Honigfeld G, Abuzzahab FS Sr, Wang R, Steinbook R, Tuason V, Klerman G: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987;7:377-384.
48. Conley RR, Schulz SC, Baker RW, Collins JF, Bell JA: Clozapine efficacy in schizophrenic nonresponders. Psychopharmacol Bull 1988;24:269-274.
49. Essali A, Al-Haj Haasan N, Li C, Rathbone J: Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2009; (1):CD000059.
50. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia: Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997;337:809-815.
51. Simonsen E, Friis S, Haahr U, Johannessen JO, Larsen TK, Melle I, Opjordsmoen S, Rund BR, Vaglum P, McGlashan T: Clinical epidemiologic first-episode psychosis: 1-year outcome and predictors. Acta Psychiat Scand 2007;116:54-61.
52. Meltzer HY, Lee M, Cola P: The evolution of treatment resistance: Biological implications. J Clin Psychopharmacol 1998;18:5S-11S. 53 Meltzer HY, Matsubara S, Lee JC: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251:238-246.
53. Azorin JM, Spiegel R, Remington G, Vanelle JM, Pere JJ, Giguere M, Bourdeix I: A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiat 2001;158:1305-1313.
54. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA: Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiat 2002;159:255-262.
55. Conley RR, Tamminga CA, Kelly DL, Richardson CM: Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiat 1999;46:73-77.
56. Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yagcioglu AE, Small JG: A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiat 2008;69: 274-285.
57. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK, CATIE Investigators: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiat 2006;163:600-610.
58. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacol (Berl) 1996;124:57-73.
59. Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiat 1996;153:321-330.
60. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY: Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiat 1993;34702-712.
61. Akdede BB, Anil Yagcioglu AE, Alptekin K, Turgut TI, Tumuklu M, Yazici MK, Jayathilake K, Tunca Z, Gogus A, Meltzer HY: A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: Effects on cognition. J Clin Psychiat. 2006;67:1912-1919.
62. McGurk SR: The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiat 1999; 60:24-29.
63. Meltzer HY, McGurk SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233-255.
64. Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR: Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: Critical examination of confounds. Neuropsychopharmacology 2003;28:1491-1500.
65. Woodward ND, Purdon SE, Meltzer HY, Zald DH: A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005;8:457-472.
66. Lindstrom LH: The effect of long-term treatment with clozapine in schizophrenia: A retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988;77:524-529.
67. Meltzer HY, Alphs LD, Bastani B, Ramirez LF, Kwon K: Clinical efficacy of clozapine in the treatment of schizophrenia. Pharmacopsychiatry 1991;24:44-45.
68. Palmer BA, Pankratz VS, Bostwick JM: The lifetime risk of suicide in schizophrenia: A reexamination. Arch Gen Psychiat 2005;62:247-253.
69. Asnis GM, Friedman TA, Sanderson WC, Kaplan ML, van Praag HM, Harkavy-Friedman JM: Suicidal behaviors in adult psychiatric outpatients. I. Description and prevalence. Am J Psychiatry 1993; 150:108-112.
70. Caldwell CB, Gottesman II: Schizophrenics kill themselves too: A review of risk factors for suicide. Schizophr Bull 1990;16:571-589.
71. Meltzer HY, Okayli G: Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-190.
72. Walker AM, Lanza LL, Arellano F, Rothman KJ: Mortality in current and former users of clozapine. Epidemiology 1997;8:671-677.
73. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S, International Suicide Prevention Trial Study Group: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT
74. Arch Gen Psychiat 2003;60:82-91.
75. Modestin J, Dal Pian D, Agarwalla P: Clozapine diminishes suicidal behavior: A retrospective evaluation of clinical records. J Clin Psychiatry 2005;66: 534-538.
76. Hennen J, Baldessarini RJ: Suicidal risk during treatment with clozapine: A meta-analysis. Schizophr Res 2005;73:139-145.
77. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J: 11-year followup of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study Lancet 2009;374:620-627.
78. Schulte PF: Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother 2006;40:683-688.
79. Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Harter S, Hiemke C: Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998;18:2-9.